DOBUTAMINE HYDROCHLORIDE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for dobutamine hydrochloride and what is the scope of patent protection?
Dobutamine hydrochloride
is the generic ingredient in four branded drugs marketed by Baxter Hlthcare, Dr Reddys, Hainan Poly, Hikma, Hospira, Luitpold, Teligent, Teva Parenteral, Watson Labs, Watson Labs Inc, and Lilly, and is included in sixteen NDAs. Additional information is available in the individual branded drug profile pages.Six suppliers are listed for this compound.
Summary for DOBUTAMINE HYDROCHLORIDE
| US Patents: | 0 |
| Tradenames: | 4 |
| Applicants: | 11 |
| NDAs: | 16 |
| Drug Master File Entries: | 12 |
| Finished Product Suppliers / Packagers: | 6 |
| Raw Ingredient (Bulk) Api Vendors: | 102 |
| Clinical Trials: | 129 |
| Patent Applications: | 1,195 |
| What excipients (inactive ingredients) are in DOBUTAMINE HYDROCHLORIDE? | DOBUTAMINE HYDROCHLORIDE excipients list |
| DailyMed Link: | DOBUTAMINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for DOBUTAMINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Chittagong Medical College | PHASE2 |
| Pi Research and Development Center, Bangladesh | PHASE2 |
| Beacon Pharmaceuticals PLC | PHASE2 |
Pharmacology for DOBUTAMINE HYDROCHLORIDE
| Drug Class | beta-Adrenergic Agonist |
| Mechanism of Action | Adrenergic beta-Agonists |
Medical Subject Heading (MeSH) Categories for DOBUTAMINE HYDROCHLORIDE
Anatomical Therapeutic Chemical (ATC) Classes for DOBUTAMINE HYDROCHLORIDE
US Patents and Regulatory Information for DOBUTAMINE HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hainan Poly | DOBUTAMINE HYDROCHLORIDE | dobutamine hydrochloride | INJECTABLE;INJECTION | 216131-001 | Dec 21, 2022 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Hospira | DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER | dobutamine hydrochloride | INJECTABLE;INJECTION | 020201-006 | Jul 7, 1994 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Dr Reddys | DOBUTAMINE HYDROCHLORIDE | dobutamine hydrochloride | INJECTABLE;INJECTION | 074995-001 | Mar 31, 1998 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Hospira | DOBUTAMINE HYDROCHLORIDE | dobutamine hydrochloride | INJECTABLE;INJECTION | 074634-001 | Sep 27, 1996 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DOBUTAMINE HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lilly | DOBUTREX | dobutamine hydrochloride | INJECTABLE;INJECTION | 017820-002 | Approved Prior to Jan 1, 1982 | 3,987,200 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch